Lexaria Bioscience (LEXX) Short Interest Ratio & Short Volume

Short interest is the volume of Lexaria Bioscience shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 158,700 shares of LEXX short. 1.12% of Lexaria Bioscience's shares are currently sold short. Learn More on Lexaria Bioscience's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LEXX shares currently have a short interest ratio of 1.0. Learn More on Lexaria Bioscience's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.12% of Lexaria Bioscience's floating shares are currently sold short.

Lexaria Bioscience currently has issued a total of 15,810,000 shares. Some of Lexaria Bioscience's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lexaria Bioscience currently has a public float of 14,170,000 shares.

1.12% of Lexaria Bioscience's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Lexaria Bioscience: Rezolute, Inc. (3.46%), Atossa Therapeutics, Inc. (9.81%), Rigel Pharmaceuticals, Inc. (3.56%), Organigram Holdings Inc. (5.21%), Puma Biotechnology, Inc. (10.94%), scPharmaceuticals Inc. (25.94%), Seres Therapeutics, Inc. (11.22%), Lifecore Biomedical, Inc. (9.51%), Skye Bioscience, Inc. (8.19%), Citius Pharmaceuticals, Inc. (6.64%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.13 billion), Royal Caribbean Cruises Ltd. ($2.77 billion), Moderna, Inc. ($2.76 billion), Coinbase Global, Inc. ($2.36 billion), Rivian Automotive, Inc. ($2.22 billion), Paychex, Inc. ($2.02 billion), Tractor Supply ($1.81 billion), Enphase Energy, Inc. ($1.65 billion), Chesapeake Energy Co. ($1.62 billion), and Lululemon Athletica Inc. ($1.58 billion). View all of the most shorted stocks.

Short selling LEXX is an investing strategy that aims to generate trading profit from Lexaria Bioscience as its price is falling. LEXX shares are trading up $0.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lexaria Bioscience occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LEXX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LEXX, twice per month. The most recent reporting period available is July, 15 2024.